

This article has been accepted for publication in ARD following peer review.
The definitive copyedited, typeset version is available online at [10.1136/annrheumdis-2019-216819](https://doi.org/10.1136/annrheumdis-2019-216819)

Is treat-to-target really working in rheumatoid arthritis? A longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM)

Sofia Ramiro*, Robert Landewé, Désirée van der Heijde, Alexandre Sepriano, Oliver FitzGerald, Mikkel Østergaard, Joanne Homik, Ori Elkayam, J Carter Thorne, Margaret Larche, Gianfranco Ferraccioli, Marina Backhaus, Gilles Boire, Bernard Combe, Thierry Schaevebeke, Alain Saraux, Maxime Dougados, Maurizio Rossini, Marcello Govoni, Luigi Sinigaglia, Alain G. Cantagrel, Cornelia F. Allaart, Cheryl Barnabe, Clifton O. Bingham III, Paul P. Tak, Dirkjan van Schaardenburg, Hilde B. Hammer, Rana Dadashova, Edna Hutchings, Joel Paschke, Walter P. Maksymowych

Sofia Ramiro, Department of Rheumatology, Leiden University Medical Center, Leiden; Zuyderland Medical Center, Heerlen, the Netherlands. sofiaramiro@gmail.com

Robert Landewé, Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, the Netherlands; Zuyderland Medical Center, Heerlen, the Netherlands. landewe@rlandewe.nl

Désirée van der Heijde, Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands. mail@dvanderheijde.nl

Alexandre Sepriano, Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands. NOVA Medical School, Universidade Nova de Lisboa, Portugal. alexsepriano@gmail.com

Oliver FitzGerald, St Vincent's University Hospital and Conway Institute for Biomolecular Research, University College Dublin, Ireland. oliver.fitzgerald@ucd.ie

Mikkel Østergaard, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. mo@dadlnet.dk

Joanne Homik, Department of Medicine, University of Alberta, Edmonton, Canada. jhomik@ualberta.ca

Ori Elkayam, Tel Aviv Sourasky Medical Center and the "Sackler" Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. oribe14@gmail.com

J Carter Thorne, Southlake Regional Health Centre, University of Toronto, Toronto, Canada. cartho@rogers.com

Maggie Larché, Departments of Medicine and Pediatrics, Divisions of Rheumatology, Clinical Immunology and Allergy, McMaster University, Hamilton, Canada. mlarche@mcmaster.ca

Gianfranco Ferraccioli, Catholic University of the Sacred Heart, Rome, Italy.
gff1990@gmail.com

Marina Backhaus, Park-Klinik Weissensee, Academic Hospital of the Charité, Berlin, Germany. backhaus@park-klinik.com

Gilles Boire, Department of Medicine/Division of Rheumatology, Centre intégré universitaire de santé et de services sociaux de l'Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l'Estrie-CHUS), University of Sherbrooke, Sherbrooke, Canada.
gilles.boire@usherbrooke.ca

Bernard Combe, CHU Montpellier and Montpellier University, Montpellier, France.
b-combe@chu-montpellier.fr

Thierry Schaefferbeke, Department of Rheumatology, FHU ACRONIM, University Hospital of Bordeaux, University of Bordeaux, France. thierry.schaefferbeke@chu-bordeaux.fr

Alain Saraux, LBAI, U1227, Université Brest, Inserm, CHU Brest, F-29200 Brest, France, France. alain.saraux@chu-brest.fr

Maxime Dougados, Rheumatology Department, Paris Descartes University, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France. maxime.dougados@aphp.fr

Maurizio Rossini, Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy. maurizio.rossini@univr.it

Marcello Govoni, Rheumatology Unit, S. Anna Hospital and University of Ferrara, Ferrara, Italy. gvl@unife.it

Luigi Sinigaglia, Department of Rheumatology, Gaetano Pini Institute, Milan, Italy.
luigi.sinigaglia@gpini.it

Alain G. Cantagrel, Department of Rheumatology, CHU Toulouse, UMR 1043, CPTP Inserm, Paul Sabatier University. Toulouse, France. cantagrel.a@chu-toulouse.fr

Cornelia F. Allaart, Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands. c.f.allaart@lumc.nl

Cheryl Barnabe, Departments of Medicine and Community Health Sciences, University of Calgary, Alberta, Canada. ccbarnab@ucalgary.ca

Clifton O. Bingham III, Johns Hopkins University, Baltimore, United States of America.
cbingha2@jhmi.edu

Paul P. Tak, Department of Clinical Immunology and Rheumatology, Amsterdam Rheumatology and Immunology Centre, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands; Department of Rheumatology, Ghent University, Ghent, Belgium; Department of Medicine, Cambridge University, Cambridge, United Kingdom. P.P.Tak@amc.uva.nl

Dirkjan van Schaardenburg, Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, the Netherlands. d.v.schaardenburg@reade.nl

Hilde B. Hammer, Diakonhjemmet Hospital, Oslo, Norway.
hildeberner.hammer@diakonsyk.no

Rana Dadashova, CaRE Arthritis LTD, Alberta, Canada. rana.dadashova@carearthritis.com

Edna Hutchings, CaRE Arthritis LTD, Alberta, Canada. edna.hutchings@carearthritis.com

Joel Paschke, CaRE Arthritis LTD, Alberta, Canada. Joel.Paschke@carearthritis.com

Walter P. Maksymowych, CaRE Arthritis LTD, and University of Alberta, Edmonton, Alberta, Canada.
walter.maksymowych@ualberta.ca

***Corresponding author:**

Sofia Ramiro, MD, PhD

Department of Rheumatology, Leiden University Medical Center, Albinusdreef 2, 2333 GA Leiden, the Netherlands

P.O. Box 9600, 2300RC Leiden, the Netherlands

Telephone: +31 71 526 32 65

E-mail: sofiaramiro@gmail.com

Keywords

Rheumatoid arthritis, Treat-to-target, Remission

Current word count (excluding title page, abstract, references, figures and tables): 2,825

Abstract

Objectives: To investigate whether following a treat-to-target (T2T)-strategy in daily clinical practice leads to more patients with rheumatoid arthritis (RA) meeting the remission target.

Methods: RA patients from 10 countries starting/changing conventional synthetic or biologic disease-modifying anti-rheumatic drugs were assessed for disease activity every 3 months for 2 years (RA BIODAM cohort). Per visit was decided whether a patient was treated according to a T2T-strategy with DAS44 remission ($DAS44 < 1.6$) as the target. Sustained T2T was defined as T2T followed in 2 consecutive visits. The main outcome was the achievement of DAS44 remission at the subsequent 3-month visit. Other outcomes were remission according to DAS28-ESR, CDAI, SDAI and ACR/EULAR Boolean definitions. The association between T2T and remission was tested in generalized estimating equations models.

Results: In total 4,356 visits of 571 patients [mean (SD) age: 56 (13) years, 78% female] were included. Appropriate application of T2T was found in 59% of the visits. T2T (vs no T2T) did not yield a higher likelihood of DAS44 remission 3 months later [OR (95%CI): 1.03 (0.92;1.16)], but sustained T2T resulted in an increased likelihood of achieving DAS44 remission [OR: 1.19 (1.03;1.39)]. Similar results were seen with DAS28-ESR remission. For more stringent definitions (CDAI, SDAI and ACR/EULAR Boolean remission), T2T was consistently positively associated with remission (OR range: 1.16-1.29), and sustained T2T had a more pronounced effect on remission (OR range: 1.49-1.52).

Conclusion: In daily clinical practice, the correct application of a T2T-strategy (especially sustained T2T) in patients with RA leads to higher rates of remission.

Key messages (up to 5 bullet points):

What is already known about this subject?

- Randomized controlled trials have demonstrated the efficacy of treat-to-target approaches in rheumatoid arthritis. Real life data from cohorts are still needed to support the widespread implementation of T2T in clinical practice.

What does this study add?

- In daily clinical practice, the correct application of a T2T-strategy in patients with RA leads to higher rates of remission as compared to not following it.
- Not only in early RA, but also in established RA, following a T2T-strategy leads to higher remission rates.

How might this impact on clinical practice or future developments?

- Rheumatologists should be encouraged to follow a T2T-strategy to contribute to the achievement of higher rates of remission for their patients.

Introduction

Early diagnosis, prompt commencement of disease modifying antirheumatic drug (DMARD) treatment and applying treat-to-target (T2T) strategies are now engrained in rheumatoid arthritis (RA) treatment paradigms. These approaches have substantially improved the outcomes of patients with RA.[1] Remission has been defined and agreed upon as the optimal target when managing a patient with RA.[2,3] Reaching the state of remission is associated with reduced radiographic progression and improved functional ability.[4]

Thoroughly monitoring disease activity, adjusting treatment according to a fixed protocol and aiming at a predefined treatment goal, the so-called T2T-strategy, has advantages over usual care.[5,6] Several strategy studies provide the basis of this evidence, namely the TICORA (Tight Control of RA study)[7] and CAMERA (Computer Assisted Management in Early RA)[8] studies. Subsequently, several strategy studies have incorporated a T2T-strategy in their treatment algorithm in the formal comparison of specific therapies, such as was done in the BeSt (Behandel Strategïën) study.[9] However, such evidence was gathered in the setting of randomized controlled trials (RCTs), with strict inclusion and exclusion criteria, following strict protocols and all particularities of RCTs. These studies provide the best evidence for the efficacy of T2T as an intervention, but to some extent compromise the generalizability of the findings, when one wants to consider applying them more broadly.

Having formally demonstrated the efficacy of T2T in RCTs, it is important to assess whether this strategy also improves outcomes in unselected patients from daily clinical practice. The first cohort studies focused on patients with very early disease and confirmed that following a standardized intensive treatment led to improved achievement of remission.[10] Subsequently, some cohort studies have shown that tight-control treatment leads to more rapid remission and higher remission achievement after 1 or 2 years than usual care.[11,12] Nevertheless, the conclusions from these 2 studies were based on an indirect comparison between 2 different cohorts (one with T2T applied and another with usual care), with different patient characteristics, and focused on the remission achievement at 1 or 2 years in the 2 cohorts. Such a comparison should ideally be made within the same cohort of patients, wherein some patients receive a T2T-strategy while others receive usual care. Real life data from cohorts without strict protocol specifications regarding choice of treatment are still needed to support the widespread implementation of T2T in clinical practice. Furthermore, previous studies have focused on the achievement of remission at a given time point, e.g. 1 or 2 years, ignoring whether or not the remission outcome was achieved in each of the visits throughout the follow-up (e.g. 3 monthly visits, per T2T recommendations). A true longitudinal analysis taking all observations over time into account, both in terms of following T2T or not, and

achieving remission or not, reflecting daily clinically practice, has not yet been conducted. Additionally, T2T has not yet been investigated in patients with established RA.

The aim of the present study was to investigate whether following a T2T-strategy leads to more patients with RA meeting the treatment target (remission) in daily clinical practice.

Methods

Study population

Patients from RA BIODAM (BIOmarkers of joint DAMage), which has been previously described, were included.[13] In brief, RA BIODAM is a 2-year multi-national prospective observational study, including patients with a clinical diagnosis of RA and also fulfilling the 2010 RA Classification Criteria,[14] recruited in daily practice from 10 countries from October 2011 to April 2015. To be eligible patients presented with active disease (44-joint disease activity score, DAS44 $>$ 2.4)[15] and were to be started on or changing DMARD treatment, including conventional synthetic DMARDs (csDMARDs) and a first tumor necrosis factor inhibitor (TNFi); patients who had prior biologic (b)DMARD experience were excluded. All patients were included in this analysis. The database used for this analysis was locked in April 2017. The study fulfilled Good Clinical Practice Guidelines, received ethical approval from the local ethics committees, and all patients provided informed consent.

Remission

Remission was the outcome of interest. According to the study protocol, patients were monitored every 3 months using DAS44 calculated with the erythrocyte sedimentation rate (ESR).[15] DAS44 remission, i.e. DAS44 $<$ 1.6[16] was therefore chosen as the main outcome for this analysis. Alternative definitions of remission were also used, namely the 28-joint disease activity score[17] (DAS28-ESR) remission (i.e. DAS28-ESR $<$ 2.6),[18] the Clinical Disease Activity Index (CDAI) remission (i.e. CDAI \leq 2.8),[19] the Simplified Disease Activity Index (SDAI) remission (SDAI \leq 3.3),[20] and the American College of Rheumatology / European League Against Rheumatism (ACR/EULAR) Boolean remission (i.e. tender joint count (TJC) \leq 1, swollen joint count (SJC) \leq 1, C-reactive protein (CRP) \leq 1mg/dL and patient global assessment (PGA) (0-10) \leq 1).[2] All definitions of remission were binary (yes/no).

Treat-to-target

Participating rheumatologists were required by protocol to follow a T2T-strategy with DAS44 remission ($DAS_{44} < 1.6$) as benchmark. In order to define whether a T2T-strategy was appropriately followed or not, every visit was checked according to pre-defined criteria. T2T was considered appropriate: i) if a patient had already a disease activity score below the target ($DAS < 1.6$) and treatment was not intensified; or ii) if treatment was intensified upon a $DAS \geq 1.6$. Treatment intensification was defined as increasing dosage or adding a drug from the following categories: csDMARDs, bDMARDs or corticosteroids. T2T was considered incorrectly applied if: i) the target was met and treatment was nevertheless intensified; or ii) the target was not met and treatment was not intensified.

Additional definitions for T2T were also considered for sensitivity analyses: i) T2T without corticosteroids, i.e. without considering corticosteroids as a treatment intensification; ii) T2T less strict, i.e. considering T2T as adequate as long as the target, DAS44 remission, is met, regardless of whether treatment is nevertheless intensified or not; iii) T2T-low disease activity (T2T-LDA) using LDA (i.e. $DAS < 2.4$) [21] instead of remission as the benchmark.

Furthermore, ‘sustained T2T’ strategy was defined as following T2T in at least 2 consecutive visits.

Other relevant clinical information

Age, gender, disease duration, rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) status (positive/negative) and being DMARD-naïve (yes vs no), all collected at baseline, were considered in this analysis as potential effect modifiers or confounders of the relationship of interest. Country of residence was also considered as a potential confounder.

Statistical analysis

The relationship between following T2T at a given visit and meeting the target of remission at the subsequent visit 3 months later was investigated using time-lagged generalized estimating equations (GEE) models. GEE is a suitable technique to make use of all available observations from each patient while adjusting for inherent within-subject correlations of the repeated measurements. Models were time-lagged to allow investigation of the effect of the main predictor of interest (i.e. following T2T) on the outcome (i.e. remission) with a lag of 3 months; in other words, with the outcome occurring 3 months later. The same analyses were conducted to investigate the effect of sustained T2T on meeting the target of remission. The ‘exchangeable’ working correlation structure, demonstrating the best fit to the data, was used.

As treatment intensification has a central role in T2T, we sought to investigate the extent to which the components of the disease activity scores contributed to it. We

therefore investigated the effect of TJC>1, SJC>1, PGA>1 and CRP>1mg/dL on treatment intensification (yes/no). This analysis was also conducted with GEE, including all above-mentioned disease activity components in one multivariable model.

For each model, interactions between the T2T variable and age, gender, disease duration and RF/ACP positivity were tested, and if significant ($p < 0.15$) and clinically relevant the model was fitted in each subgroup. If these proved to be not relevant, final models were adjusted for potential confounders selected *a priori*: age, gender, disease duration and country of residence. Stata SE version 12 was used.

Results

In total, 571 patients were included with a mean age of 56 (SD 13) years, 78% females and a mean disease duration of 6.5 (8.0) years, 37% with a disease duration up to 2 years (Table 1). In total, 78% of the patients were RF and/or ACPA positive, and 48% were DMARD-naïve at baseline (mean disease duration of 3.6 (5.6), 50% with ≤ 2 -year disease duration). At the end of the baseline visit, almost 60% of the patients were on treatment with csDMARDs only, 35% of the patients on a TNFi with a csDMARD and only 6% on TNFi monotherapy. Almost half of the patients were on corticosteroids after the baseline visit.

T2T was appropriately applied in 59% of 4,356 visits. This included 31% of patient visits where DAS44 remission was met and treatment was not intensified, and 28% of visits where treatment was appropriately escalated. In 3% of visits (9% of those with treatment intensification), treatment intensification took place even though DAS44 remission was met (making a total of 31% of the visits with treatment intensification). In the remaining 38% of visits T2T was not being followed as there was no treatment intensification despite active disease ($\text{DAS44} \geq 1.6$) (Figure 1).

Throughout the 2-year follow-up period an increasing proportion of patients met remission definitions. At 3 months 24% of the patients were in DAS44 and DAS28-ESR remission, and 8% in ACR/EULAR Boolean remission. At 24 months 52% of the patients were in DAS44 remission, also 52% in DAS28-ESR remission and 27% in ACR/EULAR Boolean remission (Figure 2).

T2T on remission outcomes

Following a T2T-strategy, as compared to not following it, was not significantly associated with a DAS44 or DAS28-ESR remission 3 months later (odds ratio (95% confidence interval) 1.03 (0.92; 1.16) and 1.03 (0.91; 1.16), respectively), but was significantly associated with ACR/EULAR Boolean remission (OR 1.16 (1.01; 1.34)) and also with CDAI remission (OR 1.29 (1.12; 1.49)) and SDAI remission (OR 1.24 (1.08; 1.41)) (Table 2). Results of the sensitivity analyses were similar, except for a

slightly stronger association between T2T and remission outcomes for both ‘T2T without corticosteroids’ and ‘T2T-REM less strict’. With T2T-LDA, with LDA as the benchmark, there was a significant association between T2T and all remission outcomes (OR between 1.3 and 1.4). None of the tested effect modifiers, namely age, gender, disease duration, seropositivity or DMARD naïve (vs not), modified the relationships of interest.

Sustained T2T on remission outcomes

Following a sustained T2T-strategy compared to not following it was associated with remission 3 months later according to all definitions, e.g. DAS44 remission OR 1.19 (1.03; 1.39) or ACR/EULAR Boolean remission (OR 1.49 (1.24;1.81)) (Table 3).

Relationship between disease activity components and treatment intensification

All disease activity components were significantly associated with treatment intensification, with SJC and TJC showing the strongest associations, also in a multivariable model including all the components: OR ‘SJC>1’ 3.42 (2.89; 4.05), OR ‘TJC>1’ 3.35 (2.72; 4.11), OR ‘PGA>1’ 2.14 (1.71; 2.68) and OR ‘CRP>1’ 2.00 (1.66; 2.42).

Discussion

In the present study we have shown that following a T2T-strategy, and particularly sustained T2T, in daily clinical practice leads to more patients with RA meeting the most stringent remission criteria over time. This is the first comprehensive analysis that considers all available visits of unselected patients who were followed by protocol for a period of 2 years. The results of the analysis provide direct evidence that following T2T, and particularly sustained T2T, immediately results in a higher likelihood of remission at the next visit, 3 months later (the longitudinal interpretation of a T2T-strategy). Moreover, we have for the first time shown that following T2T is also efficacious in patients with established RA, while previous studies focused on the effect of T2T in patients with early RA.

The strictly temporal relationship between following a T2T-strategy and meeting remission was statistically significant for almost all remission outcomes and for the different T2T definitions used. The exceptions were the DAS44 and DAS28-ESR remission definitions with an interval of 3 months only, while for sustained T2T the relationship with all remission outcomes was statistically significant. The explanation is rather technical: the independent variable (T2T with DAS44 as benchmark) and the outcome (i.e. DAS44 remission) include exactly the same disease activity score, which implies that the model becomes inherently auto-regressive. Such a scenario effectively removes the variability in the data necessary to demonstrate efficacy of an intervention. The other definitions of remission are slightly different from the

benchmark definition and allow more statistical separation. An alternative explanation is that DAS44 and DAS28-ESR definitions are more lenient in comparison to ACR/EULAR Boolean, CDAI, and SDAI remission and are more frequently met even if T2T is not applied.[2] Nevertheless, the signal that a T2T-strategy, and particularly sustained T2T-strategy, increases the likelihood of stringent remission is clear and consistent. Also, these findings became even more evident throughout the follow-up of this study. The proportion of patients achieving remission, regardless of its definition, increased substantially through follow-up (Figure 2). Even after 2 years, a plateau has not yet been reached, reassuring clinicians that if we measure disease activity and treat patients effectively over time, high remission rates can be achieved.

These findings come from a population of patients with an average of 6.5 years of disease duration. One may speculate that the effect of following T2T could be even better in early disease. In this study, we have not found any differences between patients DMARD naïve vs not and also according to disease duration, but a lack of statistical power cannot be excluded. Additionally, even patients who were DMARD naïve had a relatively long disease duration (average of 3.6 years), not being the most representative DMARD naïve patients.

If T2T is so clearly associated with clinical remission, as shown here and in the literature, [5,6] why, then, is a T2T-strategy not always followed in clinical practice? Even in this study, with a protocol requiring implementation of T2T, this strategy was ‘only’ followed in less than two thirds of the visits. Also within the RA BIODAM cohort, we have shown that, among other factors, the absence of objective signs of inflammation (e.g. swollen joints) implied a lower likelihood to follow T2T.[22] Also, in the 10-year follow-up of the BeSt trial, non-adherence to the protocol has been assigned to disagreement with how DAS reflects disease activity (felt to overestimate the real disease activity) and disagreement with the subsequently required step in the protocol.[23] Many clinicians find regularly measuring disease activity too time consuming endeavour and consider it an additional barrier to implementation of T2T.[24,25]

In order to launch new strategies or interventions in clinical practice, the formulation of recommendations, like the T2T recommendations,[27] does not suffice, and implementation should actively be promoted. Studies like ours may further corroborate the message that T2T leads to more stringent remission and may help implementation in clinical practice. Appropriate education may also help. The intervention of the TRACTION trial included one educational face-to-face meeting and monthly webinars on the principles and practical advice on implementation of T2T. A substantial improvement in the adherence to T2T was demonstrated with improvement of 46% in the arm following the training program compared to 14% in the control arm.[28] Still, rheumatologists may report compliance with recommendations but in practice do not always follow them.[29]

Some limitations of this study need to be considered. First, it is designed as an observational study reflecting daily clinical practice with unselected patients contrasting with the reality of RCTs from which most evidence on T2T originates to date. However, one may question how close to daily clinical practice the RA BIODAM cohort really is, with participation from only a few centers per country, several being tertiary referral centers, and with rheumatologists mandated to follow a strict T2T protocol. As in principle, rheumatologists were required to follow T2T per protocol, we have in this study in essence compared the visits in which the protocol was followed to others in which protocol was violated. One can therefore not exclude a bias intrinsic to this comparison. Additionally, detailed reasons for not following T2T have not been adequately registered precluding additional analysis of adherence to T2T versus taking the physician's reasoning into account. Moreover, only patients with active disease were included, and the average baseline disease activity was high. This may preclude the generalizability of the findings to patients with low disease activity, and not answer the question of whether following a T2T-strategy is beneficial in patients already in low disease activity, given the risks of overtreatment.[30,31] Lastly, when investigating the impact of following a T2T-strategy, one is not only analysing the impact of treatment intensification but implicitly one is evaluating visits in which patients are already in remission, which have accentuated the benefit of T2T. However, it was our aim to investigate the impact of following the T2T-strategy in its whole and not parts of it, as well as to take all disease activity measurements into account as the longitudinal technique chosen properly does. As a main strength, this is a multinational observational study, including unselected patients reflecting daily clinical practice, with the first truly longitudinal analysis addressing the impact of following a (sustained) T2T-strategy.

In conclusion, following a T2T-strategy, and especially sustained T2T, works in daily clinical practice and leads to more patients meeting the target, i.e. remission. Rheumatologists should be encouraged to follow a T2T-strategy to contribute to the achievement of higher rates of remission for their patients.

Acknowledgements

The authors sincerely thank the staff and all patients of the RA BIODAM study.

Author Contributions

All authors made contributions to conception and/or implementation of the study, were involved in reviewing and revising the manuscript, and gave final approval to the version to be published.

Funding

BIODAM was financially supported by an unrestricted grant from AbbVie. The funder had no role in the design, performance, analysis, interpretation or reporting of the study.

AS is supported by a doctoral grant from “Fundação para a Ciência e Tecnologia” (SFRH/BD/108246/2015).

Competing interests

Sofia Ramiro: research grants and/or consultancy fees: AbbVie, Eli Lilly, MSD, Novartis, Sanofi

Robert Landewé: Received consulting fees from AbbVie, BMS, Celgene, Eli-Lilly, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Merck, Novartis, Pfizer, Roche, UCB and is Director of Rheumatology Consultancy by

Désirée van der Heijde: Received consulting fees from AbbVie, Amgen, Astellas, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Daiichi, Eli-Lilly, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, UCB Pharma and is Director of Imaging Rheumatology bv.

Alexandre Sepriano: Received speaking fees from Novartis.

Oliver FitzGerald: Has received research grants and/or consultancy fees: AbbVie, Eli Lilly, Celgene, Novartis, UCB, Pfizer, Amgen, Janssen

Mikkel Østergaard: Has received research support, consultancy fees and/or speaker fees from Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, Sandoz, Sanofi and UCB

Joanne Homik: none

Ori Elkayam: Has received grants and personal fees from Pfizer, Abbvie, Roche, Janssen, Novartis and Lilly.

J Carter Thorne: Received research grants and/or consulting fees from AbbVie, Amgen, Celgene, Centocor, Lilly, Medexux/Medac, Merck, Novartis, Pfizer, Sandoz, Sanofi

Maggie Larche: Received advisory board honoraria from AbbVie, Actelion, Boehringer Ingelheim, BMS, Janssen, Novartis, Pfizer, Sanofi, Roche; and an unrestricted educational grant from AbbVie

Gianfranco Ferraccioli: Received research grants and/or consultancy fees from Novartis, Roche, BMS, Pfizer, AbbVie, Lilly, Janssen, MSD, Boehringer-Ingelheim, UCB.

Marina Backhaus: Received research grants from: AbbVie Co.KG, Roche, Novartis, Pfizer. Received speaking fees from: Actelion, AbbVie Co.KG, BMS, Celgene, Gilead, Janssen, Lilly, MSD, Novartis, Sanofi Genzyme, Roche, Pfizer, UCB

Gilles Boire: Received consulting fees from Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and speaker fees from BMS, Merck, Pfizer. Industry support for investigator-initiated research initiatives from Abbvie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Merck, Pfizer, Roche, UCB

Bernard Combe: Received consulting fees from AbbVie, BMS, Eli-Lilly, Gilead, Janssen, Merck, Novartis, Pfizer, Roche-Chugai, Sanofi, UCB

Thierry Schaevebeke: Received consulting fees for Lilly, Novartis, Pfizer, Sanofi – Research financial support from: Pfizer, Lilly

Alain Saraux: Research grants and/or consultancy fees from AbbVie, BMS, Chugai, Eli Lilly, MSD, Nordic pharma, Novartis, Pfizer, Sanofi, UCB

Maxime Dougados: Received research grants and/or honorarium fees for his participation at advisory boards and/or symposium organized by Pfizer, AbbVie, Lilly, Novartis, BMS, Roche, UCB, Merck.

Maurizio Rossini: Has received advisory board honoraria, consultancy fees and/or speaker fees from Abiogen, Amgen, Abbvie, BMS, Celgene, Eli-Lilly, MSD, Novartis, Pfizer, Sanofi, Sandoz, UCB

Marcello Govoni: Has received Advisory board honoraria, consultancy fees and/or speaker fees from Abbvie, Alfa-Sigma, BMS, Celgene, MSD, Novartis, Pfizer, Roche, Sanofi

Luigi Sinigaglia: has received speaker fees from Amgen, Eli Lilly, Abbvie, Roche, BMS

Alain G. Cantagrel: Received consultancy fees from BMS, Chugai, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, UCB, AbbVie, Celgene, Nordic Pharma
Received research grants from Pfizer, UCB, AbbVie, Celgene

Cornelia F. Allaart: none

Cheryl Barnabe: Advisory board honoraria from Gilead, Pfizer, Novartis, Eli Lily, Roche, Amgen; Speaking fees from UCB, BMS and Abbvie

Clifton O. Bingham III: Consultant to Abbvie, BMS, Gilead, Lilly, Pfizer, Genentech/Roche, Sanofi/Regeneron. Grant support from BMS and Janssen.

Paul P. Tak: Currently an employee of Kintai Therapeutics, Cambridge MA. Kintai Therapeutics has not been involved in this work.

Dirkjan van Schaardenburg: none

Hilde B. Hammer: Has received fees for speaking and/or consulting from AbbVie, BMS, Pfizer, UCB, Roche, MSD and Novartis.

Rana Dadashova: none

Edna Hutchings: none

Joel Paschke: none

Walter P. Maksymowych: Received consulting fees from AbbVie, Boehringer Ingelheim, Celgene, Eli-Lilly, Galapagos, Janssen, Novartis, Pfizer, UCB Pharma and is Chief Medical Officer of CARE Arthritis Limited

Patient and Public Involvement

This research was done without patient involvement. Patients were not invited to comment on the study design and were not consulted to develop patient relevant outcomes or interpret the results. Patients were not invited to contribute to the writing or editing of this document for readability or accuracy

Table 1 - Baseline characteristics

	N = 571
	Mean (SD) or n (%)
Age, years	55.7 (12.9)
Female gender	434 (76.0%)
Disease duration, years	6.5 (8.0)
Education, years	12.6 (3.8)
Number of comorbidities	1.2 (1.3)
Rheumatoid factor positivity	370 (68.0%)
Anti-CCP positivity	388 (69.3%)
RF and/or anti-CCP positivity	431 (77.7%)

DAS44 (0-10)	3.8 (1.0)
DAS28-ESR (0-10)	5.2 (1.2)
CDAI (0-76)	26.9 (11.6)
SDAI (0-86)	28.5 (12.4)
Patient global (0-10)	5.7 (2.3)
HAQ (0-3)	1.1 (0.7)
SJC (0-44)	8.4 (6.1)
TJC (0-53)	13.6 (9.1)
ESR (mm/h)	28.7 (22.2)
CRP (mg/dL)	1.5 (2.3)
Number of prior DMARDs	0.9 (1.1)
DMARD naïve	274 (48.0%)
Smoking status	
- Never smoker	282 (49.4%)
- Current smoker	161 (28.2%)
- Ex-smoker	128 (22.4%)
Treatment csDMARD/TNFi started at baseline	
- Both	196 (34.6%)
- csDMARD only	334 (58.9%)
- TNFi only	36 (6.3%)
- None	1 (0.2%)
Treatment with oral corticosteroids started at baseline	255 (45%)

Anti-CCP: anti-citrullinated protein; RF: rheumatoid factor; DAS44: 44-joint disease activity score; DAS28-ESR: 28-joint disease activity score (with erythrocyte sedimentation rate); CDAI: Clinical Disease Activity Index; SDAI: Simple Disease Activity Index; HAQ: health assessment questionnaire; SJC: swollen joint count; TJC: tender joint count; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; DMARD: disease modifying anti-rheumatic drug; csDMARD: conventional synthetic disease modifying anti-rheumatic drug; TNFi: tumor necrosis factor inhibitor

Figure 1 - Proportion of the visits (n = 4,356) in which treat-to-target strategy (with DAS44<1.6 as benchmark) is followed vs not and the details regarding the proportion of visits with target achievement and/or treatment intensification. Treatment intensification was defined as start or dosage increase of a conventional synthetic or biological disease modifying antirheumatic drug or of a corticosteroid.
DAS44: 44-joint disease activity score

Figure 2 – Proportion of achievement of the different remission outcomes throughout the 2-year follow-up. DAS44: 44-joint disease activity score; DAS28-ESR: 28-joint disease activity score; ACR: American College of Rheumatology; EULAR: European League Against Rheumatism; CDAI: Clinical Disease Activity Index; SDAI: Simple Disease Activity Index

Table 2 – Effect of following treat-to-target strategies on remission outcomes 3 months later*

	DAS44 remission (OR (95% CI))	DAS28-ESR remission (OR (95% CI))	ACR/EULAR Boolean remission (OR (95% CI))	CDAI remission (OR (95% CI))	SDAI remission (OR (95% CI))
T2T	1.03 (0.92; 1.16)	1.03 (0.91; 1.16)	1.16 (1.01; 1.34)	1.29 (1.12; 1.49)	1.24 (1.08; 1.41)
T2T without corticosteroids	1.07 (0.95; 1.20)	1.11 (0.98; 1.26)	1.23 (1.06; 1.42)	1.37 (1.18; 1.59)	1.34 (1.17; 1.53)
T2T-REM less strict	1.06 (0.94; 1.19)	1.07 (0.95; 1.21)	1.32 (1.13; 1.53)	1.43 (1.22; 1.67)	1.34 (1.17; 1.54)
T2T-LDA	1.26 (1.10; 1.44)	1.36 (1.17; 1.56)	1.27 (1.09; 1.47)	1.39 (1.18; 1.64)	1.36 (1.17; 1.59)

* All models adjusted for age, gender, disease duration and country. T2T was considered being followed: i) if a patient had already a disease activity score below the target (DAS<1.6; DAS<2.4 for LDA definition) and treatment was correctly not intensified; or ii) if treatment was intensified upon a DAS≥1.6 (or DAS ≥2.4 for LDA definition). T2T without corticosteroids: without considering corticosteroids in treatment intensification. T2T-REM less strict: considering T2T as adequate as long as the target, DAS44 remission, is met, regardless of whether treatment nevertheless intensified or not. T2T: treat-to-target; LDA: low disease activity; DAS44: 44-joint disease activity score; DAS28-ESR: 28-joint disease activity score; ACR: American College of Rheumatology; EULAR: European League Against Rheumatism; CDAI: Clinical Disease Activity Index; SDAI: Simple Disease Activity Index; OR: odds ratio; CI: confidence interval.

Table 3 - Effect of following a sustained treat-to-target strategy on remission outcomes 3 months later*

	DAS44 sustained remission (OR (95% CI))	DAS28-ESR sustained remission (OR (95% CI))	ACR/EULAR Boolean sustained remission (OR (95% CI))	CDAI sustained remission (OR (95% CI))	SDAI sustained remission (OR (95% CI))
Sustained T2T	1.19 (1.03; 1.39)	1.23 (1.06; 1.44)	1.49 (1.24; 1.81)	1.45 (1.19; 1.77)	1.52 (1.27; 1.82)

* All models adjusted for age, gender, disease duration and country. Sustained treat-to-target was considered followed if T2T was followed in ≥2 subsequent visits. T2T was considered being followed: i) if a patient had already a disease activity score below the target (DAS<1.6; DAS<2.4 for LDA definition) and treatment was correctly not intensified; or ii) if treatment was intensified upon a DAS≥1.6 (or DAS ≥2.4 for LDA definition). T2T: treat-to-target; DAS44: 44-joint disease activity score; DAS28-ESR: 28-joint disease activity score; ACR: American College of Rheumatology; EULAR: European League Against Rheumatism; CDAI: Clinical Disease Activity Index; SDAI: Simple Disease Activity Index; OR: odds ratio; CI: confidence interval.

References

1. Kievit W, Fransen J, de Waal Malefijt MC, et al. Treatment changes and improved outcomes in RA: an overview of a large inception cohort from 1989 to 2009. *Rheumatology* 2013;**52**:1500-8
2. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. *Annals of the rheumatic diseases* 2011;**70**:404-13
3. Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Annals of the rheumatic diseases* 2017;**76**:960-77
4. van Tuyl LH, Felson DT, Wells G, et al. Evidence for predictive validity of remission on long-term outcome in rheumatoid arthritis: a systematic review. *Arthritis care & research* 2010;**62**:108-17
5. Schoels M, Knevel R, Aletaha D, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. *Annals of the rheumatic diseases* 2010;**69**:638-43
6. Schipper LG, van Hulst LT, Grol R, et al. Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome. *Rheumatology* 2010;**49**:2154-64
7. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. *Lancet* 2004;**364**:263-9
8. Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). *Annals of the rheumatic diseases* 2007;**66**:1443-9
9. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. *Arthritis and rheumatism* 2005;**52**:3381-90
10. Vermeer M, Kuper HH, Hoekstra M, et al. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study. *Arthritis and rheumatism* 2011;**63**:2865-72
11. Schipper LG, Vermeer M, Kuper HH, et al. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. *Annals of the rheumatic diseases* 2012;**71**:845-50
12. Brinkmann GH, Norvang V, Norli ES, et al. Treat to target strategy in early rheumatoid arthritis versus routine care - A comparative clinical practice study. *Seminars in arthritis and rheumatism* 2018
13. Maksymowych WP, FitzGerald O, Ostergaard M, et al. The International RA BIODAM Cohort for Validation of Soluble Biomarkers in Rheumatoid Arthritis: Study Design. *J Rheumatol*, accepted for publication 2019
14. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Annals of the rheumatic diseases* 2010;**69**:1580-8

15. van der Heijde DM, van 't Hof MA, van Riel PL, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. *Annals of the rheumatic diseases* 1990;**49**:916-20
16. Prevoo ML, van Gestel AM, van THMA, et al. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. *Br J Rheumatol* 1996;**35**:1101-5
17. Prevoo ML, van 't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. *Arthritis and rheumatism* 1995;**38**:44-8
18. Fransen J, Creemers MC, Van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. *Rheumatology* 2004;**43**:1252-5
19. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. *Clinical and experimental rheumatology* 2005;**23**:S100-8
20. Aletaha D, Ward MM, Machold KP, et al. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. *Arthritis and rheumatism* 2005;**52**:2625-36
21. van Gestel AM, Prevoo ML, van 't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. *Arthritis and rheumatism* 1996;**39**:34-40
22. Sepriano A, Ramiro S, FitzGerald O, et al. Adherence to Treat-to-Target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort. *The Journal of rheumatology* 2019
23. Markusse IM, Dirven L, Han KH, et al. Evaluating Adherence to a Treat-to-Target Protocol in Recent-Onset Rheumatoid Arthritis: Reasons for Compliance and Hesitation. *Arthritis care & research* 2016;**68**:446-53
24. Pincus T, Segurado OG. Most visits of most patients with rheumatoid arthritis to most rheumatologists do not include a formal quantitative joint count. *Annals of the rheumatic diseases* 2006;**65**:820-2
25. Yazici Y, Bergman M, Pincus T. Time to score quantitative rheumatoid arthritis measures: 28-Joint Count, Disease Activity Score, Health Assessment Questionnaire (HAQ), Multidimensional HAQ (MDHAQ), and Routine Assessment of Patient Index Data (RAPID) scores. *The Journal of rheumatology* 2008;**35**:603-9
26. Ferreira RJO, Carvalho PD, Ndosi M, et al. Impact of patient global assessment on achieving remission in patients with rheumatoid arthritis: a multinational study using the METEOR database. *Arthritis Care and Research* 2019
27. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. *Annals of the rheumatic diseases* 2016;**75**:3-15
28. Solomon DH, Losina E, Lu B, et al. Implementation of Treat-to-Target in Rheumatoid Arthritis Through a Learning Collaborative: Results of a Randomized Controlled Trial. *Arthritis Rheumatol* 2017;**69**:1374-80
29. Gvozdenovic E, Allaart CF, van der Heijde D, et al. When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical

practice? Results of the International Recommendation Implementation Study (IRIS).
RMD Open 2016;**2**:e000221

30. Landewe RBM. Overdiagnosis and overtreatment in rheumatology: a little caution is in order. *Annals of the rheumatic diseases* 2018;**77**:1394-96
31. Bergstra SA, Olivas O, Akdemir G, et al. Further Treatment Intensification in Undifferentiated and Rheumatoid Arthritis Patients Already in Low Disease Activity has Limited Benefit towards Physical Functioning. *Arthritis research & therapy* 2017;**19**:220